Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012
- 10 March 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (8) , 1014-1021
- https://doi.org/10.1200/jco.2009.27.6543
Abstract
Purpose Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (stand...This publication has 19 references indexed in Scilit:
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJournal of Clinical Investigation, 2006
- Survival in Patients With Desmoplastic MelanomaJournal of Clinical Oncology, 2006
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 WeeksJournal of Clinical Oncology, 2005
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast GroupJournal of Clinical Oncology, 2005
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.2003
- G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cellsBiochemical and Biophysical Research Communications, 2002
- Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast CancerJournal of Clinical Oncology, 2002